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differential processing of proenkephalinergic and proopiome-
lanocortin (POMC) systems among controls, prolactin-secreting
microadenomas, and non-secreting macroadenomas. We will pre-
sent our discovery data on growth hormone (GH) isoforms, dif-
ferentially expressed proteins (n = 56) between controls and
macroadenomas, novel phosphoproteins, and oxidative stress
nitroproteins (NS). All of these data profoundly impact on our
knowledge of human neuroendocrinology.
S-39-3
Omics in precision medicine
J. Bergquist
Analytical Chemistry and Neurochemistry, Department of
Chemistry – Biomedical Centre, Uppsala University, Uppsala,
Sweden
It has been estimated that only Alzheimer’s disease (AD) alone,
the most common form of dementia, will affect approximately 81
million individuals by 2040. To date, the actual cause and cascade
of events in the progression of many neurological and neurodegen-
erative diseases have not been fully determined. Furthermore, there
is no definitive blood test or simple diagnostic method for many
of those diseases so far available. Fibril formation of proteins,
together with a dysfunctional regulation of lipids and steroids, has
been shown to play a fundamental role influencing various risk
factors of neurodegeneration and pathogenesis. Recently, there has
been a stronger focus on proteomics and metabolomics (e.g. lipi-
domic) studies with the hope of increasing our understanding of
the underlying mechanisms leading to disease. Technological
advancements in high-resolution mass spectrometry and rapid
improvements in chromatographic techniques have led to quick
expansion of the field of in this research. In this presentation,
emphasis is given to the new developments in technologies and
their applications in disease biomarker discovery.
S-39-2
Large-scale label-free clinical proteomics and
phosphoproteomics for precision medicine
C. Jimenez
OncoProteomics Laboratory, Department of Medical Oncology,
VUmc-Cancer Center Amsterdam, Amsterdam, the Netherlands,
Amsterdam, Netherlands
The general goal of our clinical cancer proteomics efforts is to
disclose tumor biology and drive improved diagnostics, treatment
and management of cancer. To this end, we use label-free mass
spectrometry-based proteomics that is optimally suited for large-
scale clinical sample profiling. I will highlight our work in vari-
ous cancer types with a focus on exosome proteomics for non-
invasive diagnostics and phosphoproteomics for response predic-
tion. More specifically, I will discuss our prostate cancer effort
that made use of an innovative workflow for high-throughput
extracellular vesicle proteomics applied to prostate cancer cell
lines and urinary patient samples. Furthermore I will highlight
our newly developed computational analysis approach for Inte-
grative inferred kinase activity (INKA) analysis that can rank
kinase activities in mass spectrometry-based phosphoproteome
data derived from single samples. We show that INKA can
uncover oncogenes, differential kinase activity and drug targets.
We believe that cancer proteomics powered by precise measure-
ments and dedicated analysis will realize the full potential of mul-
ti-parameter diagnostics and personalized medicine.
ShT-39-1
Semi-targeted metabolomic studies of
methamphetamine’s biotransformations and
its impact on macrophage’s secreted
metabolome
K. Pawlak1, K. Lech2, A. Vei3, A. Harwood3, P. Ciborowski3
1Faculty of Chemistry, Warsaw University of Technology,
Warsaw, Poland, 2Faculty of Chemistry, Warsaw University of
Technology, Warszawa, Poland, 3Department of Pharmacology
and Experimental Neuroscience, University of Nebraska Medical
Center (UNMC), Omaha, United States of America
Methamphetamine (MA) is an illegal psychostimulant. Despite
the prevalence of MA addiction, its effect on the innate immune
system is not known. Several reports showed the effect of MA on
various aspects of intracellular signaling, yet changes in intracel-
lular and secreted metabolomes induced by MA in human mono-
cyte derived macrophages (hMDM) has been understudied. In
this study, we used a semi-targeted metabolomic approach to
investigate the effect of MA on macrophages secreted metabo-
lism. Culture supernatants from hMDM exposed to MA or con-
trols were subjected to solid phase extraction (SPE, Plexa PCX)
or liquid-liquid extraction and followed by reversed phase chro-
matography performed with two columns connected in-line (EC
50/2 Nucleodur C18 Pyramid, 3 lm and EC 150/2.1 Cogent,
UDC-Cholesterol, 4 lm). A QTRAP 6500 MS/MS System with a
Turbo Spray ion source (SCIEX, Framingham, MA, USA) work-
ing in multiple reaction monitoring mode (MRM) was used as a
detection system. Selected MRM list was based on research
papers, databases (e.g. HMDB, METLIN). During analytical
work-flow, identity verification was found as the most critical
step. It was performed using enhanced product ion mode (EPI)
supported by a chemical characteristic of analytes (RPLC –
polarity and SPE – acid-base properties). Results presented in
this paper describe three novel aspects of metabolomic research.
First, we present an attempt to analyze the metabolic secretome
of hMDM exposed to Meth in comparison to non-exposed con-
trol cells. We measured 94 metabolites and identified 11 that were
significantly different between control and Meth-exposed macro-
phages. Our new analytical approach, utilizing combined C18
and Cogent columns, allowed us to separate and identify OHMA
isomers. Lastly, we have found two presumably unknown
metabolites pending structural determination and confirmation.
This work is supported by R01 DA043258 and P30 MH062261
grants from National Institutes of Health (USA).
ShT-39-2
Development of a diagnostic SARI test system
based on protein microchip for detection and
forecasting the severity of acute respiratory
infections
A. Taraskin1,2, A. Lozhkov1, M. Plotnikova1, S. Klotchenko1
1Smorodintsev Research Institute of Influenza, Saint-Petersburg,
Russia, 2Peter the Great St. Petersburg Polytechnic University,
Saint-Petersburg, Russia
According to the World Health Organization (WHO), acute res-
piratory viral infections cause the overwhelming majority of all
reported infectious diseases, yet methods for their molecular diag-
nosis are limited. The purpose of this study is to develop a multi-
parameter diagnostic assay, including a set of reagents, based on
protein microchip technology, which allows personalized diagno-
sis of influenza-like illnesses and severe acute respiratory infec-
tions (SARI). Ideally, such diagnostics will be capable of
determining etiological agents and providing prognostic
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